FDA Approval Marks a Milestone in Presbyopia Treatment
On July 31, 2025, LENZ Therapeutics announced that the U.S. Food and Drug Administration (FDA) had approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved to treat presbyopia—the age-related decline in near vision affecting over 128 million American adults. LENZ Therapeutics, Inc.
How VIZZ Works: The “Pinhole Effect”
Unlike previous treatments that stimulate the eye’s focusing muscles, VIZZ targets the iris. Its active ingredient, aceclidine, contracts the iris sphincter muscle—shrinking the pupil to less than 2 mm. This creates a “pinhole effect,” increasing depth of focus and sharpening near vision without blurring distance vision or causing a myopic shift.
Clinical Data: Rapid Relief That Lasts
VIZZ’s approval stems from strong results in three Phase 3 trials—CLARITY 1 and 2 (42 days) and CLARITY 3 (six months)—involving nearly 30,000 treatment-days. Within 30 minutes, users achieved significant near-vision improvement lasting up to 10 hours. Notably, in CLARITY 1 and 2, 65–71% of participants gained three or more lines of near visual acuity without losing distance clarity.
Safety Profile: Generally Mild, Transient Effects
Across trials, no serious treatment-related adverse events emerged. Common side effects—typically mild and self-resolving—included instillation-site irritation, dim vision, and headache, reported in approximately 20%, 16%, and 13% of users, respectively. Additional mild events—such as conjunctival and ocular hyperemia—were noted in over 5% of participants.
Prescribing Guidelines & Warnings
-
Usage: Administer one drop per eye, wait 2 minutes, then instill a second drop—once daily.
-
Precautions:
-
Blurred vision post-instillation: Patients should avoid driving or operating machinery until vision clears.
-
Retinal risks: Rare cases of retinal tear or detachment have been reported with miotics; a baseline eye exam is recommended, and medical care should be sought if hotspots like flashing lights, floaters, or vision loss occur.
-
Contact lenses: Remove before use; can be reinserted 10 minutes after instillation.
-
Convenience Meets Innovation
VIZZ represents a non-invasive, once-daily alternative to reading glasses and multifocal contacts. Sample distributions are expected to begin in October 2025, with broad commercial availability slated for mid-Q4 2025. LENZ Therapeutics, Inc.
According to LENZ’s CEO, this approval is a transformative leap for presbyopia care—an attainable, daily-use treatment that could become a new standard of care.
Why VIZZ Stands Out
-
Mechanistically refined: Targets pupil constriction—not focusing muscles—reducing side effects seen in treatments like pilocarpine-based drops.New AtlasWikipedia
-
Fast-acting & durable: Clear near vision in about 30 minutes, lasting up to 10 hours.
-
Solid safety track record: Minimal, mild side effects and robust trial data.
Final Thought
With the FDA’s approval of VIZZ, presbyopia—a near-inevitable consequence of aging—now has a promising, prescription-only alternative that could free many from the daily reliance on reading glasses. Still, proper screening and patient education about temporary dimness and retinal risks remain essential. As samples hit eye-care professionals’ hands this fall and consumers gain access later in 2025, the future of convenient near-vision correction is taking bright shape.
References:
Clinical efficacy and safety details were confirmed via LENZ’s FDA press release LENZ Therapeutics, Inc. and comprehensive prescribing info FDA Access Data. Additional validation and expert commentary came from Nature NatureWikipedia, New Atlas New Atlas, Pharmacy Times, and HealthDay/Health News outlets.
